Renal sympathetic denervation for blood pressure control: a review of the current evidence and ongoing studies

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Hypertension Research

Background:

• Hypertensive heart disease is a leading cause of mortality in the US.
• Autonomic nervous system imbalance, specifically sympathetic overactivity, contributes to hypertension and heart disease.
• Current medical therapies for hypertensive heart disease remain challenging to manage effectively.

Purpose of the Study:

• To review developments in renal sympathetic denervation (RSD) for resistant hypertension.
• To discuss the implications of recent clinical trial outcomes on RSD.
• To explore the role of autonomic nervous system modulation in hypertensive heart disease.

Main Methods:

• Review of current literature on renal sympathetic denervation.
• Analysis of outcomes from the Symplicity HTN-3 trial.
• Discussion of the pathophysiology linking sympathetic nervous system activity to hypertension.

Main Results:

• Early results for renal sympathetic denervation were encouraging.
• The Symplicity HTN-3 trial did not meet its primary efficacy endpoint.
• Optimism surrounding RSD has been tempered by recent trial results.

Conclusions:

• Renal sympathetic denervation remains an area of active investigation for resistant hypertension.
• Further research is required to clarify the efficacy and optimal application of RSD.
• Understanding the role of sympathetic nervous system modulation is crucial for treating hypertensive heart disease.